NMN and NR supplements: what the evidence says about NAD precursors and aging

Nicotinamide adenine dinucleotide, or NAD, is a coenzyme found in every living cell. It shuttles electrons in metabolic reactions. Without it, mitochondria cannot convert nutrients into energy. NAD levels decline with age, falling by roughly 50 percent between age 40 and 70 in multiple cross-sectional studies.

That decline prompted a wave of interest in supplementing NAD precursors. The two most studied are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Both raise NAD levels in humans. Whether doing so slows, delays, or reverses aging is the question that has generated hundreds of millions of dollars in supplement sales and considerably less certainty in the clinical literature.

What NMN and NR do at the cellular level

Both NR and NMN are precursors to NAD. The body’s NAD synthesis uses a salvage pathway: NAD is consumed by enzymes like PARPs and CD38, broken into nicotinamide, and then rebuilt through intermediates that include NR and NMN. Supplementing either precursor increases the pool of available intermediates and, in theory, raises NAD levels.

A 2023 study in Science confirmed that oral NR and NMN both raise blood NAD levels in middle-aged and older adults, with peak increases at 4 to 8 hours after dosing. The effect is dose-dependent up to about 1,000 mg daily, after which the curve flattens. The NAD increase is measurable, but whether it produces clinically meaningful outcomes is far less clear.

What the human trials show

A 2023 randomized controlled trial in Nature Communications tested NMN at 250 mg daily in 66 adults aged 40 to 65 over 12 weeks. The NMN group showed a statistically significant improvement in a composite measure of physical performance that included gait speed and grip strength. Individual measures trended in the right direction but most did not reach significance on their own. A 2024 trial in GeroScience using 500 mg of NR daily in 80 adults over age 60 for 16 weeks found no significant difference between placebo and NR for any of the primary endpoints, which included mitochondrial function measured by phosphorus-31 magnetic resonance spectroscopy, muscle strength, and fatigue.

A 2021 study in Nature Aging tested a different NAD precursor, nicotinamide, along with other compounds in a cocktail approach and reported modest improvements in a DNA methylation-based aging clock. The sample was 43 healthy men, duration was 12 months, and the effect size was roughly 1.5 years of biological age reduction by the clock’s estimate. The significance of DNA methylation clock changes remains debated, as different clocks return different results and correlations with hard outcomes are still being established.

The NMN regulatory situation

The FDA’s position on NMN has been inconsistent. In 2022, the agency determined that NMN could not be marketed as a dietary supplement because it had been investigated as a drug (by Metro International Biotech, which is pursuing NMN as a treatment for Friedreich’s ataxia). The FDA has since signaled flexibility and NMN remains available through many online retailers, but its regulatory status in the US is unsettled. NR, in contrast, is generally recognized as safe and has not faced the same regulatory scrutiny.

Who might benefit

The strongest signal in the NAD precursor literature is for conditions of metabolic stress. A 2022 trial in Cell Metabolism found that NR improved markers of non-alcoholic fatty liver disease and reduced circulating inflammatory cytokines in overweight adults. Other trials have found modest improvements in insulin sensitivity and blood pressure, though findings are inconsistent across studies.

For healthy young or middle-aged adults, there is no evidence that boosting NAD above normal levels produces any benefit. NAD does not work like a vitamin — it is not that more is better above a certain threshold. The precursor supplements appear to restore low NAD to normal levels, but do not push NAD above a physiological ceiling. That ceiling appears to be tightly regulated.

Safety and side effects

Both NR and NMN are well-tolerated in the published trial data. The most common side effects are mild and include nausea, flushing, and headache. No serious adverse events attributable to the supplements have been reported in trials up to 12 months in duration. Longer-term safety data is unavailable. Both compounds are relatively expensive, with typical monthly costs of $40 to $80 for a 300 mg to 500 mg daily dose from reputable manufacturers.

The gap between the evidence and the marketing

NAD precursor marketing routinely invokes the language of longevity science in ways the trial data cannot support. Phrases like “reverse aging” and “activate longevity genes” appear on product pages alongside references to David Sinclair’s work at Harvard, even though Sinclair’s most dramatic results come from mouse models using genetic manipulation, not oral supplementation available to consumers.

The sirtuin activation hypothesis, which posits that NAD-boosting activates a family of proteins called sirtuins that protect against aging, is a compelling scientific framework. But human trials testing whether oral NR or NMN meaningfully activate sirtuins in vivo have not produced clear dose-response data. The pathway exists in cell culture. Whether it matters in humans taking over-the-counter supplements is unproven.

Niacin (vitamin B3) and nicotinamide are cheaper NAD precursors with decades of safety data. They also raise NAD levels, though through slightly different metabolic routes. For someone interested in the NAD restoration hypothesis, ensuring adequate B3 intake — either through diet or a standard B-complex supplement — is the evidence-based starting point. The premium precursors may offer advantages in specific contexts, but the trial data has not yet established a clear margin of benefit over their cheaper alternatives.